Vomiting
Vomiting represents one of the more disruptive GI side effects of tirzepatide, occurring in approximately 17% of users with abdominal injection versus 8% with thigh injection—more than halving incidence through site selection alone. This dramatic difference suggests local mechanisms influence GI tolerance.
Whilst less common than nausea, vomiting can significantly impact quality of life during treatment. Understanding that injection technique can reduce this risk enables proactive management rather than reactive dose adjustment.
Our content on managing GLP-1 side effects covers practical strategies including site rotation. Understanding the site-effect relationship helps clients optimise their treatment experience.
Learn More
This topic is discussed in 4 articles:
-
GI side effect showing dramatic variation by site: 17% with abdominal injection versus 8% with thigh – more than halved.
-
While many patients experience positive weight loss results from Mounjaro injections, here’s what you should know about tiredness as a potential side effect of Mounjaro.
-
Some Mounjaro users may experience side effects such as constipation. We look at ways to manage it effectively.
-
Pelvic organ prolapse often results from weakened pelvic floor muscles and connective tissues. Find out how our non-invasive EMS therapies can help manage and treat pelvic floor issues.